CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients

ανά Matsushita, M, Ozawa, K, Suzuki, T, Nakamura, M, Nakano, N, Kanchi, S, Ichikawa, D, Matsuki, E, Sakurai, M, Karigane, D, Kasahara, H, Tsukamoto, N, Shimizu, T, Mori, T, Nakajima, H, Okamoto, S, Kawakami, Y, Hattori, Y
Τόπος έκδοσης Blood Cancer J (2017)